Ocuphire Pharma, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Marketable Securities (Tables)

Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2013

Schedule Of Cost And Fair Value Of Marketable Securities



		Cost		Gross Unrealized		Fair
Securities available-for-sale		Basis		Gains/(Losses)		Value
December 31, 2013:
State and municipal obligations	$	100,000	$	-	$	100,000

December 31, 2012:
State and municipal obligations	$	100,000	$	-	$	100,000

Schedule Of Cost And Fair Value By Contractual Maturity



	Cost		Fair
Maturity	Basis		Value
10 years or more	$	100,000	$	100,000

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References + Details